US · EDIT
Editas Medicine, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02141
- Website
- editasmedicine.com
Price · as of 2024-12-31
$2.90
Market cap 214.76M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $21.63 | +645.86% |
| Intrinsic Value(DCF) | $2.48 | -14.48% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $137.99 | +4,658.31% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $31.25 | ||||
| 2016 | $25.06 | $98.49 | $0.80 | $0.00 | $0.00 |
| 2017 | $44.08 | $55.43 | $1.77 | $0.00 | $0.00 |
| 2018 | $22.60 | $53.40 | $60,956.45 | $0.00 | $0.00 |
| 2019 | $23.97 | $33.03 | $2.11 | $0.00 | $69.87 |
| 2020 | $46.28 | $67.80 | $12,458.57 | $0.00 | $0.00 |
| 2021 | $15.06 | $28.94 | $4.68 | $0.00 | $172.37 |
| 2022 | $7.83 | $22.40 | $1.50 | $0.00 | $43.91 |
| 2023 | $9.16 | $45.64 | $7.04 | $0.00 | $0.00 |
| 2024 | $1.72 | $21.63 | $0.00 | $0.00 | $137.99 |
AI valuation
Our deep-learning model estimates Editas Medicine, Inc.'s (EDIT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $21.63
- Current price
- $2.90
- AI upside
- +645.86%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.48
-14.48% upside
Graham-Dodd
—
— upside
Graham Formula
$137.99
+4,658.31% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EDIT | Editas Medicine, Inc. | $2.90 | 214.76M | +646% | -14% | — | +4,658% | -0.60 | 1.05 | 4.38 | 0.40 | -1.40 | 1.05 | 100.00% | -777.22% | -733.72% | -98.10% | 1925.86% | -56.40% | 0.26 | — | 3.75 | 3.71 | 0.41 | 4257.00% | -5864.00% | 6005.00% | -154.71% | -2.72 | 1680.16% | 0.00% | 0.00% | 15.11% | 0.37 | 0.43 | -2.89 | -7.20 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| AVIR | Atea Pharmaceuticals, Inc… | $4.68 | 365.63M | — | — | — | — | -1.50 | 0.57 | — | 1.53 | -6.59 | 0.57 | 0.00% | — | — | -33.88% | 1111.34% | -31.78% | 0.00 | — | 24.85 | 24.44 | 0.48 | 2270.00% | — | 5867.00% | -53.78% | -7.28 | 780.43% | 0.00% | 0.00% | 0.00% | 1.04 | 1.48 | — | 4.54 |
| CABA | Cabaletta Bio, Inc. | $3.32 | 319.6M | — | — | — | — | -0.79 | 0.60 | — | 0.51 | -1.89 | 0.60 | 0.00% | — | — | -59.64% | -6352.34% | -52.82% | 0.10 | -167.30 | 6.15 | 6.05 | 1.35 | 4182.00% | — | 6674.00% | -98.71% | -3.26 | -4590.51% | 0.00% | 0.00% | 0.00% | 0.45 | 0.63 | — | -2.29 |
| CAPR | Capricor Therapeutics, In… | $27.93 | 1.28B | -15% | -76% | — | -88% | -11.15 | 3.10 | 20.26 | -7.32 | -28.92 | 3.10 | -124.37% | -191.13% | -181.71% | -48.16% | 442.17% | -35.31% | 0.01 | — | 7.77 | 7.70 | 0.24 | 3855.00% | -1155.00% | 5025.00% | -9.21% | -1.90 | 431.47% | 0.00% | 0.00% | 0.00% | -7.07 | -7.25 | 13.52 | 9.49 |
| IMMP | Immutep Limited | $2.80 | 412.14M | +523% | -76% | — | — | -5.97 | 2.55 | 72.72 | -3.80 | -35.82 | 2.69 | -1117.55% | -2506.49% | -1218.02% | -36.88% | -1019.26% | -34.27% | 0.01 | — | 11.69 | 10.17 | 1.05 | 1667.00% | 3128.00% | 7368.00% | -16.93% | -4.86 | -500.64% | 0.00% | 0.00% | 0.00% | -1.89 | -3.84 | 47.33 | 10.94 |
| KYTX | Kyverna Therapeutics, Inc… | $8.21 | 359.53M | — | — | — | — | -0.78 | 0.37 | — | 1.42 | 0.00 | 0.37 | 0.00% | — | — | -80.74% | 2732.66% | -67.12% | 0.03 | -1004.25 | 8.61 | 8.47 | 0.71 | 332990000.00% | — | 11960.00% | -116.84% | -3.38 | 2231.58% | 0.00% | 0.00% | 63.02% | 1.25 | 1.53 | — | -0.17 |
| LYEL | Lyell Immunopharma, Inc. | $24.00 | 509.85M | -75% | -75% | — | +4,553% | -0.57 | 0.51 | 3184.91 | 0.58 | -1.41 | 0.51 | 100.00% | -588122.95% | -562285.25% | -66.10% | -295.08% | -55.28% | 0.15 | — | 7.06 | 6.89 | 0.23 | 4014.00% | -5308.00% | -212.00% | -83.83% | -3.02 | -133.95% | 0.00% | 0.00% | 0.00% | 0.33 | 0.72 | -1922.61 | -4.37 |
| PRQR | ProQR Therapeutics N.V. | $1.59 | 167.5M | +4,852% | +2,420% | — | — | -4.80 | 1.50 | 7.05 | -0.05 | — | 1.50 | 100.00% | -161.18% | -146.86% | -41.35% | 56.30% | -17.34% | 0.19 | -28.29 | 3.95 | 3.84 | 5.48 | -286.00% | 19022.00% | -28740.00% | -28.37% | -0.94 | 70.36% | 0.00% | 0.00% | 16.97% | -0.04 | -0.03 | 0.06 | -2.22 |
| VNDA | Vanda Pharmaceuticals Inc… | $8.91 | 526.65M | +158% | -50% | — | — | -2.18 | 1.47 | 2.23 | -1.65 | -0.20 | 2.29 | 93.96% | -69.95% | -102.02% | -50.93% | -119.87% | -38.51% | 0.04 | — | 2.39 | 2.19 | 0.52 | 106875.00% | 872.00% | 57976.00% | -22.94% | -0.75 | -87.57% | 0.00% | 0.00% | 0.00% | -1.52 | -2.08 | 1.07 | 0.57 |
| VYGR | Voyager Therapeutics, Inc… | $4.10 | 227.96M | +883% | -19% | — | +1,465% | -3.78 | 0.82 | 3.07 | -0.29 | — | 0.82 | 100.00% | -104.11% | -81.25% | -24.25% | -162.45% | -17.47% | 0.15 | — | 5.56 | 5.45 | 0.35 | -13805.00% | -6800.00% | -12522.00% | -7.67% | -0.31 | -36.73% | 0.00% | 0.00% | 0.00% | -0.27 | -1.21 | 0.28 | 0.62 |
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
- CEO
- Gilmore O'Neill
- Employees
- 246
- Beta
- 2.19
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.48 ÷ $2.90) − 1 = -14.48% (DCF, example).